Reference products and their biosimilars
Each biosimilar’s 4Q26 payment limit compared with its reference product, per billing unit.
Prices are from the CMS payment limit files. Which biosimilar goes with which reference product comes from the site’s own biosimilar groups list, not from CMS; only entries checked by hand are shown.
| Molecule | Reference product | Biosimilars | Average vs. reference | Lowest |
|---|---|---|---|---|
| Aflibercept | Eylea J0178 | 1 | ↑ 5.7% | Pavblu ↑ 5.7% |
| Bevacizumab | Avastin J9035 | 5 | ↓ 37.1% | Vegzelma ↓ 72.0% |
| Denosumab | Prolia J0897 | 6 | ↓ 27.3% | Enoby ↓ 74.3% |
| Eculizumab | Soliris J1299 | 2 | ↓ 17.8% | Epysqli ↓ 27.9% |
| Epoetin alfa | Epogen J0885 | 1 | ↑ 22.5% | Retacrit ↑ 22.5% |
| Filgrastim | Neupogen J1442 | 4 | ↓ 49.7% | Releuko ↓ 69.0% |
| Infliximab | Remicade J1745 | 3 | ↓ 0.9% | Renflexis ↓ 14.1% |
| Natalizumab | Tysabri J2323 | 1 | ↑ 2.0% | Tyruko ↑ 2.0% |
| Pegfilgrastim | Neulasta J2506 | 6 | ↓ 26.6% | Fulphila ↓ 72.2% |
| Ranibizumab | Lucentis J2778 | 3 | ↑ 351.0% | Nufymco 0.0% |
| Rituximab | Rituxan J9312 | 3 | ↓ 70.9% | Ruxience ↓ 92.0% |
| Tocilizumab | Actemra J3262 | 3 | ↓ 23.8% | Avtozma ↓ 41.8% |
| Trastuzumab | Herceptin J9355 | 6 | ↓ 46.0% | Trazimera ↓ 83.6% |
| Ustekinumab | Stelara J3358 | 7 | ↓ 30.5% | Wezlana ↓ 77.8% |
Average vs. reference is the simple average of each biosimilar’s percent difference from the reference product’s payment limit. Groupings from reference/biosimilar_groups/2026-10-17T183707Z_d3109bb50c53.csv.